OMP 131R10 companion diagnostic

Drug Profile

OMP 131R10 companion diagnostic

Latest Information Update: 27 Jul 2016

Price : $50

At a glance

  • Originator Guardant Health; OncoMed Pharmaceuticals
  • Class Diagnostic agents
  • Mechanism of Action RSPO3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 14 Jul 2016 Phase-I clinical trials in Cancer (Diagnosis) in USA (unspecified route)
  • 14 Jul 2016 Guardant Health and OncoMed Pharmaceuticals agree to co-develop OMP 131R10 companion diagnostic
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top